कृपया अन्य खोज का प्रयास करें
Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Gary Jonathan Phillips | 60 | 2003 | CEO, MD & Director |
Hashan De Silva | - | 2023 | Non-Executive Director |
Alan Duncan Robertson | 67 | 1999 | Member of Scientific Advisory Board |
Darren Kelly | - | 2017 | Member of Scientific Advisory Board |
Jacob George | - | - | Member of Scientific Advisory Board |
Carol Pollock | - | - | Member of Scientific Advisory Board |
Neil Graham | 65 | 2020 | Non-Executive Director |
Andrew Boyle | - | - | Member of Scientific Advisory Board |
Malcolm John McComas | 68 | 2003 | Independent Director |
Kathleen M. Metters | 66 | 2017 | Member of Scientific Advisory Board & Independent Chair |
Simon Green | - | 2022 | Independent Non-Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है